<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727008</url>
  </required_header>
  <id_info>
    <org_study_id>MCART-001</org_study_id>
    <nct_id>NCT04727008</nct_id>
  </id_info>
  <brief_title>CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma</brief_title>
  <official_title>Phase I Study of A CXCR4 Modified BCMA CAR-T in Patients With Refractory and/or Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually&#xD;
      relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a&#xD;
      cell surface receptor that expressed primarily by malignant and normal plasma cells. This&#xD;
      study aims to evaluate the safety and tolerance CXCR4 modified BCMA CAR T cells in treating&#xD;
      standard treatment failed refractory/relapsed multiple myeloma, and will follow&#xD;
      dose-escalating cohorts. The efficacy of CXCR4 modified BCMA CAR T will also be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 3, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLT)</measure>
    <time_frame>2 years</time_frame>
    <description>Dose Limiting Toxicities (DLTs) during the first 28 days after anti-BCMA CAR-T cell administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (overall response rate)</measure>
    <time_frame>3 months，6 months</time_frame>
    <description>Proportion of subjects with the best overall response (BOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR (complete response rate)</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of subjects with the BOR of sCR+CR at Month 3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CXCR4 modified anti-BCMA CAR T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR T cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CXCR4 modified anti-BCMA CAR T cells</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>CXCR4 modified anti-BCMA CAR T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 to 75 years old.&#xD;
&#xD;
          2. The expected survival ≥ 12 week&#xD;
&#xD;
          3. ECOG ≤ 2&#xD;
&#xD;
          4. Patients with multiple myeloma that never achieved MR (minor response) or received ≥ 1&#xD;
             line of standard therapy but tumor relapse&#xD;
&#xD;
          5. The liver and renal function is good/adequate organ function; no uncontrolled or&#xD;
             active infectious disease&#xD;
&#xD;
          6. Venous channel is unobstructed, which can meet the needs of intravenous drip; no&#xD;
             contraindications of mononuclear cell collection&#xD;
&#xD;
          7. Patients can take effective contraceptive measures during the trial period and 1 year&#xD;
             after the infusion&#xD;
&#xD;
          8. Voluntary informed consent is given, agree to follow the trial treatment and visit&#xD;
             plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other uncontrollable cancer&#xD;
&#xD;
          2. Active hepatitis B, hepatitis C, or HIV infection&#xD;
&#xD;
          3. Other uncontrolled active disease&#xD;
&#xD;
          4. Patients with coronary heart disease, angina pectoris, myocardial infarction, cerebral&#xD;
             thrombosis, cerebral hemorrhage or any other severe diseases&#xD;
&#xD;
          5. Patients with uncontrollable hypertension(≥ grade II)&#xD;
&#xD;
          6. Patients with history of uncontrollable mental illness&#xD;
&#xD;
          7. Long-term use of immunosuppressants after organ transplantation (inhaled&#xD;
             corticosteroids are excluded)&#xD;
&#xD;
          8. Unstable pulmonary embolism or any arteriovenous embolism 30 days before enrollment;&#xD;
&#xD;
          9. Pregnant or lactating women; Men or women who have a pregnancy plan within a year; The&#xD;
             patients cannot guarantee effective contraceptive measures during the trial period;&#xD;
&#xD;
         10. Patients with uncontrollable infectious disease or need systematic treatment within&#xD;
             the 14 days of enrollment;&#xD;
&#xD;
         11. Patients had other conditions that were not appropriate for the study determined by&#xD;
             the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DAN LI, Ph.D</last_name>
    <phone>+86(028)85423525</phone>
    <email>lidan@wchscu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FUCHUN GUO, MD</last_name>
    <phone>+86(028)85423525</phone>
    <email>FCguo0797@wchscu.cn</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Ting Niu</investigator_full_name>
    <investigator_title>Director of Department of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

